STAT+: Can iTeos and GSK solve TIGIT’s troubles?
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
Category: Adam’s Biotech Scorecard
STAT+: The business of CRISPR’d medicine: Not great
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
STAT+: A strong start for Madrigal’s MASH drug launch
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
STAT+: On Andrew Left and the government’s fraud case
I love the Summer Olympics. Every four years I transform into a huge fan of…
STAT+: A preview of Neurocrine’s muscarinic drug readout
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
STAT+: Novartis not ready to admit a $3 billion mistake
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
STAT+: A primer on HELIOS-B, an enormous stock-moving event for Alnylam Pharmaceuticals
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
STAT+: Will Geron be acquired? The long-short view
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
STAT+: PDS Biotech’s survival benefit is absurdly overstated
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers…
STAT+: Cytokinetics set to pitch its heart drug to physicians — and Big Pharma suitors
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers…
STAT+: Novartis’ $3 billion MorphoSys boondoggle
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers…
STAT+: Profiting from ‘legal’ insider trading isn’t always easy
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers…
STAT+: Taking stock of the frenzied push into autoimmune disease
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers…
STAT+: The inside story of Enhertu’s pan-tumor approval
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers…
STAT+: Weed for weight loss, and more from Biotech Land
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers…
STAT+: A contrarian view on Viking Therapeutics, biotech’s hottest obesity stock
This is the inaugural edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers…